Immatics takes up the SPAC baton

With Immunovant’s bubble deflating fast the biotech Spac story is in desperate need of new ambassadors. Today the German group Immmatics made a strong bid to become this business model’s poster child, climbing on reports of efficacy with its autologous engineered T-cell receptor (TCR) projects.